Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > converting data

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Aug 31, 2021 10:35am

196 Views

Post# 33787513

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:converting data

fredgoodwinson wrote: Thanks for making me re-read that snb altough having done so would conclude the opposite.

The completion of non-GLP was previously scheduled for Q2 2021 but still remains a 'strategic objective' i.e. it hasn`t happened yet and GLP won`t start until it has.

Will they really be going to the Clinic with Rutherrin in 2022 at this rate?

Likely not without a partner, Yet it seems now they could get their NMIBC %s up, so a partner is more likely now. Money is the barrier to GLP Phase 1s either way. IMO they will get the non GMO completed early 2022, Covid did slow this process ~ 9 months :-(

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter